What GHRP-6 is
GHRP-6 is a synthetic hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. Cyril Bowers and colleagues at Tulane University described it in 1984 after screening a series of enkephalin-derived analogues for pituitary activity (Bowers et al., Endocrinology, 114(5):1537, 1984). The compound released growth hormone in a dose-dependent way, both in cultured pituitary cells and in live rats, without a matching rise in other pituitary hormones.
That selectivity for GH over other pituitary output was the finding that mattered. Until then, growth hormone-releasing hormone (GHRH) was the only known route to trigger a GH pulse pharmacologically. GHRP-6 showed a second, chemically unrelated route existed, one that acted on a receptor nobody had identified yet.
The 1984 paper measured GHRP-6's effect against several other pituitary hormones directly in the same animals. Circulating prolactin, thyroid-stimulating hormone, luteinizing hormone, and follicle-stimulating hormone did not change significantly after GHRP-6 administration, even at doses that produced a clear GH rise. That hormone-specific profile is what separated GHRP-6 from earlier, less targeted secretagogue candidates.
Mechanism: the receptor GHRP-6 was built for, before it had a name
GHRP-6 works through the growth hormone secretagogue receptor, GHS-R1a, a G-protein coupled receptor expressed on pituitary somatotrophs and in the hypothalamic arcuate nucleus. For 15 years after Bowers first described GHRP-6, researchers knew the receptor existed and could be activated synthetically, but had no endogenous ligand to compare it against.
That changed in 1999, when Kojima and colleagues purified a 28-amino acid acylated peptide from rat stomach extracts and showed it activated GHS-R1a with high potency (Kojima et al., Nature, 402:656, 1999). They named it ghrelin. GHRP-6 turned out to be a synthetic agonist for a receptor whose natural hormone had not yet been found when the peptide was first synthesized. This is why GHRP-6 is described as a ghrelin mimetic rather than a ghrelin analogue: the two share a receptor, not a structure.
GHS-R1a signals through a different pathway than the GHRH receptor. GHRH-R activation raises cyclic AMP through Gs-protein coupling. GHS-R1a instead couples to Gq, activating phospholipase C and raising intracellular calcium. Because the two receptors converge on the same somatotroph cell through separate routes, pairing a GHRH-receptor agonist with a GHS-R1a agonist like GHRP-6 produces a larger GH pulse than either alone, a synergy documented directly in the Cordido obesity data below.
GHRP-6 research: human GH secretion data
Pandya et al. tested whether GHRP-6 needs intact hypothalamic GHRH signaling to release GH, using a GHRH receptor antagonist in nine healthy men aged 20 to 30 (Pandya et al., J Clin Endocrinol Metab, 83(4):1186, 1998). Blocking the GHRH receptor substantially blunted the GH response to GHRP-6, even though GHRP-6 does not bind that receptor directly. The result placed GHRP-6's primary site of action at the hypothalamus, working through GHRH neurons, rather than acting purely on the pituitary in isolation.
A separate line of work used GHRP-6 combined with GHRH as a diagnostic stimulation test. Cordido et al. gave obese subjects, who typically show a blunted GH response to GHRH alone, both compounds together and measured a mean peak GH concentration of 42.2 ± 10.9 µg/L with an area under the curve of 1894 ± 784 µg/L per minute (Cordido et al., J Clin Endocrinol Metab, 76(4):819, 1993). That output far exceeded what either compound produced alone, and it showed the pituitary's capacity to secrete GH was intact in obesity. The defect responsible for low GH output in obese patients sits upstream, at the hypothalamic or ghrelin-signaling level, not in the somatotroph itself.
Appetite effects and the receptor GHRP-6 shares with ghrelin
Because GHRP-6 activates GHS-R1a, it triggers the same orexigenic pathway ghrelin uses to signal hunger. Wren et al. administered ghrelin and GH secretagogues centrally in rats and found both increased food intake and activated neurons in hypothalamic regions associated with appetite, including the arcuate nucleus (Wren et al., Endocrinology, 143(1):155, 2002). This is a direct receptor-level effect, not a downstream consequence of the GH pulse itself.
The appetite effect is one reason GHRP-6 is not a clean tool for isolating GH-axis outcomes from feeding behavior in research designs. Any protocol using GHRP-6 in a model with food access needs to account for the confound, since a change in body composition or metabolic markers could reflect increased caloric intake rather than the GH response alone.
GHS-R1a is expressed on neuropeptide Y and agouti-related peptide neurons in the arcuate nucleus, the same neuron population ghrelin activates to drive feeding. GHRP-6's access to this receptor means any dose sufficient to release GH also engages these neurons to some degree, since both effects run through the same binding site rather than separate GH-specific and appetite-specific receptors.
GHRP-6 compared with later secretagogues
GHRP-6 was developed alongside a family of related hexapeptides, including hexarelin, which shares the GH-releasing mechanism but carries distinct cardiac effects documented separately (see the hexarelin research overview). GHRP-2 followed as a more potent variant, and ipamorelin arrived last, purpose-built to avoid the cortisol and ACTH release both older hexapeptides carry with them.
Raun et al. compared ipamorelin against GHRP-6 and GHRP-2 in a conscious swine model and found that GHRP-6 and GHRP-2 raised ACTH and cortisol at GH-releasing doses, while ipamorelin did not produce a significant rise in either at its effective dose (Raun et al., Eur J Endocrinol, 139(5):552, 1998).
That difference matters for study design. A cortisol rise independently affects muscle protein turnover, immune markers, and fat metabolism, so a compound that raises cortisol alongside GH introduces a second variable into any downstream measurement. GHRP-6 remains useful where GHS-R1a activation itself, including its ghrelin-linked effects, is the object of study. For protocols aiming to isolate the GH axis with fewer secondary hormone shifts, see the CJC-1295 and ipamorelin research overview, which covers the CJC-1295 and ipamorelin combination in more detail.
Handling and storage considerations
GHRP-6 is supplied as a lyophilized powder and follows the same general stability profile as other short synthetic peptides: stable for extended periods when frozen and unreconstituted, more fragile once dissolved. In Indonesian conditions, ambient heat and humidity accelerate degradation of any reconstituted peptide left outside refrigeration, which is covered in more detail in the lyophilized peptide storage guide.
Researchers calculating injection volumes from a given reconstitution concentration can use the dosing calculator to convert between mass, concentration, and volume for a given protocol.
State of the evidence as of mid-2026
The human data on GHRP-6 is decades old but consistent: it reliably releases GH through a hypothalamic-dependent mechanism, and the combined GHRH plus GHRP-6 test still appears in clinical endocrinology literature as a diagnostic tool for GH deficiency, not as a treatment. The appetite mechanism is better characterized now than it was in the 1990s, largely because of ghrelin research published after 1999.
No completed Phase 3 trial exists for GHRP-6 as a therapeutic agent for any indication, and no regulatory agency has approved it for clinical use. Current research interest centers on GHS-R1a pharmacology broadly, using GHRP-6 as one of several tool compounds alongside ghrelin, GHRP-2, hexarelin, and ipamorelin to map receptor behavior across GH release, appetite, and cardiovascular endpoints.